LUPUS NEPHRITIS (LN)

This early-stage study tests a new drug called HB2198 in 30 adults with moderate-to-severe lupus, including kidney inflammation. The drug is designed to target and deplete certain immune cells (B cells) that drive the disease. The main goals are to check safety, find the best dos…

This early-stage study tests a new cell treatment called YTS109 in about 18 adults with autoimmune diseases like lupus or scleroderma that have not responded to standard therapies. Participants receive a single infusion of these modified immune cells. The main goal is to check sa…

This study tests a new cell therapy called CART19 for teens and young adults (ages 12-29) with severe lupus that hasn't responded to other treatments. The therapy uses the patient's own immune cells to target and reduce lupus activity. The goal is to control the disease and reduc…

This early-stage study is testing a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of these specially designed immune cells. The m…

This study tests a new treatment using a patient's own immune cells, modified to attack lupus-causing cells, for people with severe lupus that hasn't responded to standard therapies. About 18 participants aged 3 to 65 will receive the therapy and be monitored for safety and disea…

This early-stage study tests a new cell therapy called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and Sjogren's syndrome. Participants receive a single infusion of these specially designed cells. The main goal is to see if the treatment is safe, and res…

This study tests an experimental drug for lupus nephritis, a kidney disease caused by lupus. The main goal is to see if the drug is safe and tolerable over the long term. About 90 people with hard-to-treat lupus nephritis will take part. The drug is given for a short time, but pa…

This early-phase study tests whether a new drug, ONTO1, is safe and tolerable for people with lupus nephritis or systemic lupus erythematosus (SLE). Researchers will also see if adding ONTO1 to standard lupus treatments can improve symptoms. The study enrolls 61 adults with activ…

This study tests whether newer biologic drugs (belimumab or telitacicept) can control active lupus kidney disease better than the standard treatment. About 50 adults with biopsy-confirmed lupus nephritis will receive either a biologic plus steroids, standard therapy (mycophenolat…

This study tests a new drug (HLX79) combined with an existing antibody treatment (rituximab) in people with active kidney inflammation called glomerulonephritis. The goal is to see if the combination is safe and helps control the disease better than rituximab alone. About 24 adul…

This study tests an experimental tablet called HSK39297 in people with lupus nephritis, a kidney complication of lupus. About 105 adults will receive either the drug or a placebo daily for several months. The main goal is to see if the drug reduces protein in the urine, a sign of…

This study is a fully online registry for adults and children with lupus. It aims to collect information about diagnosis, treatment, and quality of life through surveys every six months. No travel is required—everything is done from home. The goal is to better understand lupus an…